Antimalarial MMV’183 is a clinical development candidate

TropIQ’s parasitology platform drove the optimisation of pantothenamide compounds that generated MMV’183: a candidate for further clinical development with a new mode of action for treatment of malaria and blocking transmission. The results of the research that led to the discovery of this molecule are now published by Nature Communications.



Read more